NanoString Technologies - NSTG Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NanoString Technologies in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NSTG shares.
View NSTG analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 1 year price objectives for NanoString Technologies' shares. Their NSTG share price forecasts range from $14.00 to $37.00. On average, they predict the company's stock price to reach $20.57 in the next year. This suggests a possible upside of 121.0% from the stock's current price.
View analysts price targets for NSTG or view top-rated stocks among Wall Street analysts.

NanoString Technologies' stock was trading at $7.97 at the start of the year. Since then, NSTG stock has increased by 16.8% and is now trading at $9.31.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our NSTG earnings forecast.

NanoString Technologies, Inc. (NASDAQ:NSTG) posted its earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by $0.16. The biotechnology company had revenue of $37.15 million for the quarter, compared to analyst estimates of $37.35 million. NanoString Technologies had a negative net margin of 125.37% and a negative trailing twelve-month return on equity of 165.02%. During the same period in the previous year, the company posted ($0.56) EPS.

ETFs with the largest weight of NanoString Technologies (NASDAQ:NSTG) stock in their portfolio include ROBO Global Healthcare Technology and Innovation ETF (HTEC), Global X Genomics & Biotechnology ETF (GNOM), Invesco Nasdaq Future Gen 200 ETF (QQQS), WisdomTree BioRevolution Fund (WDNA), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and iShares U.S. Medical Devices ETF (IHI).

NanoString Technologies issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $170.00 million-$180.00 million, compared to the consensus revenue estimate of $174.31 million.

36 employees have rated NanoString Technologies Chief Executive Officer Brad Gray on Glassdoor.com. Brad Gray has an approval rating of 65% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoString Technologies investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Precision Drilling (PD), AutoZone (AZO), Designer Brands (DBI), Bank of the Ozarks (OZRK) and Vista Outdoor (VSTO).

NanoString Technologies trades on the NASDAQ under the ticker symbol "NSTG."

NanoString Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avidity Partners Management LP (4.41%), Platinum Investment Management Ltd. (2.70%), Bank of America Corp DE (2.09%), Geode Capital Management LLC (1.75%), Assenagon Asset Management S.A. (1.55%) and Fisher Asset Management LLC (1.42%). Insiders that own company stock include Charles P Waite Jr, Elisha W Finney, Gregory Norden, J Chad Brown, Joseph M Beechem, K Thomas Bailey, Kirk Malloy, R Bradley Gray and Robert Hershberg.
View institutional ownership trends.

Shares of NSTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NSTG stock can currently be purchased for approximately $9.31.

NanoString Technologies (NASDAQ:NSTG) has a market capitalization of $435.61 million and generates $127.26 million in revenue each year. The biotechnology company earns $-159,540,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis.

The company employs 766 workers across the globe.

NanoString Technologies' mailing address is 530 FAIRVIEW AVENUE NORTH SUITE 2000, SEATTLE WA, 98109. The official website for the company is www.nanostring.com. The biotechnology company can be reached via phone at (888) 358-6266, via email at dfarrell@nanostring.com, or via fax at 206-378-6288.